ArticleAmerican journal of translational research2016
Effect of bisphenol a on occurrence and progression of prolactinoma and its underlying mechanisms.
Article in American journal of translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 10 citations in OpenAlex.
- Alteration of Extracellular Matrix Components in the Anterior Pituitary Gland of Neonatal Rats Induced by a Maternal Bisphenol A Diet during Pregnancy.International journal of molecular sciences · 2021Article
- Low dose of Bisphenol A enhance the susceptibility of thyroid carcinoma stimulated by DHPN and iodine excess in F344 rats.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of Bisphenol A (BPA) on prolactin (PRL) release, pituitary cell proliferation, prolactinoma formation in estrogen-sensitive Fischer 344 (F344) rats. MATERIALS AND
methodsFour-week-old female F344 rats were orally administered with different concentrations of BPA or intraperitoneal injection of estradiol benzoate (estradiolbenzoate, E2) for 12 weeks. Bodyweight, blood RPL level and pituitary weights were observed and recorded. Real-time PCR, western blot and immunohistochemistry analysis were used to detect the mRNA and protein levels of the proliferation markers, including proliferating cell neclear antigen (PCNA), pituitary tumor-transforming gene (PTTG) and its relevant marker ERα. Plasma and urine BPA concentration in patients with prolactinoma and healthy participants were measured as well.
resultsBody weights of the rats treated with BPA were significantly decreased compared with those in the control group. The plasma PRL level and the pituitary weights of the rats were higher than those in the control group after BPA treatment. Compared with the control group, the pituitary mRNA and protein expression levels of PCNA and PTTG were significantly increased after BPA treatment. Moreover, ERα expression level was enhanced by the treatment of BPA in comparison with that of the control group. Finally, the plasma BPA concentration in the prolactin tumor patients was significantly higher than that in the healthy participants.
conclusionBPA can significantly promote pituitary cell proliferation and prolactin secretion in F344 rats, which may have impact on the proliferation and secretion of pituitary cell function through the ERα pathway.
Indexed as
Identifiers
27830003PMC5095312W2552234326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.